文献速递淋巴瘤

诱导性Cd79b突变使Myd88驱动的弥漫性大B细胞淋巴瘤小鼠模型对依鲁替尼敏感

An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2024-01-01

研究构建模拟MYD88、CD79B、BCL2及浆细胞分化阻滞相关病变的弥漫性大B细胞淋巴瘤(DLBCL)小鼠模型,发现经典Cd79b ITAM突变不加速Myd88和BCL2驱动的淋巴瘤发生,但Cd79b突变淋巴瘤富集IgM表面表达并形成含MYD88、CD79B、MALT1和BTK的胞质信号复合物,BTK抑制可破坏该复合物,且携带Cd79b和Myd88联合突变的淋巴瘤对依鲁替尼敏感。

要点

  • 经典Cd79b ITAM突变不加速Myd88和BCL2驱动的淋巴瘤发生。
  • Cd79b突变小鼠DLBCL富集IgM表面表达,类似人类对应肿瘤。
  • Cd79b和Myd88联合突变淋巴瘤对依鲁替尼敏感。

核心结论

  • Cd79b和Myd88联合突变的淋巴瘤对依鲁替尼敏感,BTK抑制可破坏含MYD88、CD79B、MALT1和BTK的胞质信号复合物。

研究设计与样本

  • 研究生成了一系列模拟该DLBCL亚群的自发性小鼠模型,并重点聚焦Cd79b突变在该背景下的影响。

主要发现

  • 经典Cd79b ITAM突变不加速Myd88和BCL2驱动的淋巴瘤发生。
  • Cd79b突变小鼠DLBCL富集IgM表面表达,类似人类对应肿瘤。
  • Cd79b突变淋巴瘤显示含MYD88、CD79B、MALT1和BTK的胞质信号复合物 robust 形成,药理BTK抑制可破坏这些复合物。
  • BTK抑制剂介导的信号复合物破坏转化为携带Cd79b和Myd88联合突变淋巴瘤的选择性依鲁替尼敏感。

临床怎么用

  • 作者认为该跨物种比较为DLBCL分子靶向治疗干预策略的开发提供了框架。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma and constitutes a highly heterogenous disease. Recent comprehensive genomic profiling revealed the identity of numerous molecularly defined DLBCL subtypes, including a cluster which is characterized by recurrent aberrations in MYD88, CD79B, and BCL2, as well as various lesions promoting a block in plasma cell differentiation, including PRDM1, TBL1XR1, and SPIB. Here, we generated a series of autochthonous mouse models to mimic this DLBCL cluster and specifically focused on the impact of Cd79b mutations in this setting. We show that canonical Cd79b immunoreceptor tyrosine-based activation motif (ITAM) mutations do not accelerate Myd88- and BCL2-driven lymphomagenesis. Cd79b-mutant murine DLBCL were enriched for IgM surface expression, reminiscent of their human counterparts. Moreover, Cd79b-mutant lymphomas displayed a robust formation of cytoplasmic signaling complexes involving MYD88, CD79B, MALT1, and BTK. These complexes were disrupted upon pharmacological BTK inhibition. The BTK inhibitor-mediated disruption of these signaling complexes translated into a selective ibrutinib sensitivity of lymphomas harboring combined Cd79b and Myd88 mutations. Altogether, this in-depth cross-species comparison provides a framework for the development of molecularly targeted therapeutic intervention strategies in DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Flümann R, Hansen J, Meinel J, et al. An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma. Blood Adv. 2024. PMID: 38060829. doi:10.1182/bloodadvances.2023011213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。